Top Providence, RI Biotech Companies (6)
Don't see your company?
Create a company profile
Advanced Image Enhancement's (AIE) core technology evolved from proprietary United States Navy signal and image processing research
Nabsys uses proprietary electronic nano-channel detectors to analyze long DNA molecules at high velocity. Electronic detection enables Nabsys to achieve significantly higher resolution than can be obtained using optical mapping methods. Nabsys HD-Mapping™ solid-state electronic nano-channel detectors build whole genome maps with sub-diffraction-limit resolution that are truly high definition. These maps offer compelling advantages for the analysis of structural variation, the assembly of genomes, and as a method for confirming putative variants called using other technologies. HD-Mapping works by adding sequence-specific tags to long DNA molecules. These molecules pass through the nano-detectors at high velocity using a combination of electrophoretic and hydrodynamic control. The detectors report the locations of the sequence-specific tags on the molecules. The information is then analyzed by Nabsys analytical software. Key application areas that are enabled by Nabsys include: • De Novo Assembly • Structural Variant Discovery • Variant Verification • Microbiome Analysis • Metagenome Characterization • Hybrid Assembly Nabsys provides the complete solution for electronic genome mapping. The Nabsys HD-Mapping platform includes: • HD-Mapping instrument • Electronic nano-channel detector chips • Complete run reagent cartridge • Sample prep kit • Comprehensive control and data analysis software Nabsys HD Mapping provides routine, accurate, cost-effective analysis of genomic structural information. The HD-Mapping platform employs fully electronic detection of tagged single DNA molecules to provide significantly higher sensitivity, accuracy, scalability and speed of detection in comparison to existing mapping technologies. Single-molecule reads, hundreds of kilobases in length, have high resolution and low error rates, resulting in high information content per read.
www.andrewalliance.com Andrew Alliance is a company wholly owned by Waters Corporation, and is based in Geneva, Boston and Paris. The company was created in March 2011, and acquired by Waters in January 2020. Andrew Alliance is dedicated to advance science by working with scientists to create a new class of easy-to-use robots and connected devices that take repeatability, performance, and efficiency of laboratory experiments to the level required by 21-st century biology.
High Purity New England has grown from a small team of three people to a deeply experienced organization that employs over 200 professionals committed to advancing their customers' bioprocessing objectives from discovery to commercial launch. Their insight into the changing needs of the bioprocessing industry led to their state-of-the-art facility being the first in the Northeastern United States to receive ISO 9001:2015 certification for the specific application of design, development, manufacturing, and distribution of single-use assemblies. They acquired their third facility and are in the process of constructing a new cleanroom manufacturing suite, lab, distribution center, and further office spaces for their growing teams. They are excited to continue to anticipate and meet the needs of a rapidly growing industry in the decades to come.
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn more at www.waters.com.
EpiVax is Hiring! Please see our Careers Page - http://epivax.com/about-us/careers EpiVax uses immune-engineering to develop new vaccines and to improve the immunogenicity profiles of new drugs. The company is well known for its independent thinking and interdisciplinary scientists. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity" meetings. By 2006, EpiVax had developed a reputation as “thought leaders” in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to <20 for its competitors). The EpiVax team also prides itself on delivering on promises. “We maintain a close relationship with our clients,” De Groot says. We aim to treat our clients with respect and provide capable, intelligent solutions for their needs.” The company's motto is "Fearless Science". For up to date news about the endeavors of our Fearless Scientists, read our blog: http://epivax.com/press/thinking-out-loud-blog
Work Your Passion. Live Your Purpose.
